Shares of Emergent Biosolutions Inc (NYSE:EBS) have been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $61.86.
A number of analysts have recently issued reports on EBS shares. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a report on Tuesday, July 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $62.00 price target on shares of Emergent Biosolutions in a report on Thursday, August 2nd. Chardan Capital raised their price target on shares of Emergent Biosolutions from $53.00 to $57.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Wells Fargo & Co set a $61.00 price target on shares of Emergent Biosolutions and gave the company a “hold” rating in a report on Friday, August 10th. Finally, Cowen reaffirmed a “hold” rating and set a $49.00 price target on shares of Emergent Biosolutions in a report on Wednesday, August 29th.
In other news, CEO Daniel Abdun-Nabi sold 90,776 shares of the stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $60.18, for a total value of $5,462,899.68. Following the transaction, the chief executive officer now owns 257,343 shares in the company, valued at approximately $15,486,901.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald Richard sold 7,893 shares of the stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $60.02, for a total transaction of $473,737.86. Following the completion of the transaction, the director now owns 21,063 shares in the company, valued at approximately $1,264,201.26. The disclosure for this sale can be found here. Insiders sold a total of 164,626 shares of company stock worth $9,895,754 in the last quarter. Company insiders own 13.40% of the company’s stock.
Several large investors have recently modified their holdings of EBS. Wells Fargo & Company MN lifted its stake in shares of Emergent Biosolutions by 11.4% in the 1st quarter. Wells Fargo & Company MN now owns 147,357 shares of the biopharmaceutical company’s stock worth $7,759,000 after purchasing an additional 15,052 shares during the period. SG Americas Securities LLC bought a new stake in Emergent Biosolutions during the 1st quarter worth approximately $171,000. Financial Gravity Wealth Inc. bought a new stake in Emergent Biosolutions during the 1st quarter worth approximately $190,000. New York State Common Retirement Fund raised its stake in Emergent Biosolutions by 33.7% during the 1st quarter. New York State Common Retirement Fund now owns 76,881 shares of the biopharmaceutical company’s stock worth $4,048,000 after acquiring an additional 19,371 shares during the period. Finally, California Public Employees Retirement System raised its stake in Emergent Biosolutions by 5.3% during the 1st quarter. California Public Employees Retirement System now owns 57,607 shares of the biopharmaceutical company’s stock worth $3,033,000 after acquiring an additional 2,912 shares during the period. Hedge funds and other institutional investors own 83.00% of the company’s stock.
Shares of NYSE EBS opened at $60.80 on Wednesday. The company has a current ratio of 5.59, a quick ratio of 4.15 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.29 billion, a PE ratio of 32.00, a P/E/G ratio of 1.40 and a beta of 1.23. Emergent Biosolutions has a 52-week low of $36.38 and a 52-week high of $67.24.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.19. The firm had revenue of $220.20 million for the quarter, compared to the consensus estimate of $208.94 million. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. The business’s quarterly revenue was up 118.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.13 EPS. On average, equities research analysts forecast that Emergent Biosolutions will post 2.35 earnings per share for the current fiscal year.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.